Adaptive biotechnologies corporation - sequence-based detection of minimal residual disease (MRD) in acute lymphoblastic leukemia patients.

Ended Purchase Order Awarded Last action

Contract number
HHSN261201600569P
Awardee
Awarding agency
Obligated
$25,025

Award facts

Opportunity
Contract value 25% obligated
  • $25,025.00 Current, with exercised options
  • $101,575.00 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
NAICS code
621511 Medical Laboratories
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Seattle, WA 98102, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00001 -$17,550
Original award $42,575

About this award

The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for sequence-based detection of minimal residual disease in acute lymphoblastic leukemia patients, valued at $101,575, on September 21, 2016. Performance is located in Seattle, Washington. The order carries a firm fixed price and an ultimate completion date of September 20, 2018.

Quick answers

Who was awarded contract HHSN261201600569P?

HHSN261201600569P was awarded to Adaptive Biotechnologies Corporation by National Cancer Institute (National Institutes of Health) on September 21, 2016.

How much is contract HHSN261201600569P worth?

The government has obligated $25,025 on HHSN261201600569P. Its potential value, with all options, is $101,575.

Was contract HHSN261201600569P competed?

The extent of competition for HHSN261201600569P was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award